title: Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.
abstract: Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.
authors: Unit of Neuromuscular and Neurodegenerative Diseases, Department of Neurosciences, IRCCS Bambino Gesù Pediatric Children's Hospital, P.zza S. Onofrio 4, 00165 Rome, Italy. adeledamico@hotmail.com
authors: Adele
authors: A
authors: D'Amico
authors: Michela
authors: M
authors: Catteruccia
authors: Fabrizio
authors: F
authors: De Benedetti
authors: Marina
authors: M
authors: Vivarelli
authors: Manuela
authors: M
authors: Colucci
authors: Simona
authors: S
authors: Cascioli
authors: Enrico
authors: E
authors: Bertini
mesh_terms: D017668:Age of Onset; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D002648:Child; D004594:Electrophysiology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000188:drug therapy* / Q000503:physiopathology; D000069283:Rituximab; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab